ClinicalTrials.gg
RecruitingNCT07237269Updated Oct 19, 2026

Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer

A Phase 2 interventional study of Androgen Deprivation Therapy (ADT) and Abiraterone in Prostate Cancer, sponsored by University of Nebraska. Recruiting at 1 site in United States. Open to male participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by University of Nebraska · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 19, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
30 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 126 studies testing abiraterone in Prostatic Neoplasms — 17 open to participants now, 37 under way, 5 of them phase 3. abiraterone · Prostatic Neoplasms.

Planned enrollment
24th of 126
140 · median 51
Started
2026
with 1 other
Phase 2
79 of 126
13 open now
Primary completion
2033-04
later than 36 of 36 live
Registered
124th of 126
by date

Among the 126 studies testing abiraterone in Prostatic Neoplasms, this one is the 24th largest by planned enrollment, is one of 2 that started in 2026, is one of 79 in phase 2, reaches primary completion later than 36 of the 36 other live ones, and was the 124th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 126 studies testing abiraterone in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About abiraterone

abiraterone: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 30 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing abiraterone in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The advent of PSMA-PET has improved sensitivity and specificity in staging prostate cancer, particularly in intermediate- and high-risk disease. This has created uncertainty in the management of patients with PSMA-positive but conventionally negative pelvic lymphadenopathy (i.e., \<1 cm in smallest diameter).

This study evaluates outcomes of enhanced androgen deprivation therapy (ADT) with abiraterone and prednisone compared to standard ADT, both in combination with radiation therapy, in patients with prostate cancer and PSMA-positive but conventionally negative pelvic lymphadenopathy.

A total of 140 eligible participants will be randomized to receive either enhanced ADT with abiraterone and prednisone or standard ADT, both with concurrent radiation therapy. Participants will be followed for 5 years after completion of ADT to assess outcomes.

The primary objective is to determine whether enhanced ADT improves 5-year failure-free survival compared to standard ADT. Secondary objectives include evaluation of toxicity, quality of life, biochemical progression-free survival, cancer-specific survival, overall survival, and metastasis-free survival.

Exploratory objectives include evaluation of tumor growth and regression rates using PSA values and assessment of the relationship between treatment outcomes and blood-based heme oxygenase-1 (HO-1) levels.

Read the detailed description

The advent of PSMA-PET has allowed greater sensitivity and specificity when staging prostate cancers, particularly intermediate and high-risk prostate cancers. This has created a gap in knowledge regarding the treatment of patients who have PSMA-positive but conventionally negative pelvic lymphadenopathy (i.e. \<1cm in smallest diameter). The purpose of this study is to compare outcomes of enhanced ADT with abiraterone and prednisone and standard ADT, both alongside radiation therapy, in prostate cancer patients with PSMA-positive but conventionally negative pelvic lymphadenopathy. We hypothesize that enhanced ADT with abiraterone and prednisone is superior to standard ADT for the treatment of prostate cancer patients with PSMA-positive but conventionally negative pelvic lymphadenopathy. We further hypothesize that standard ADT will be associated with a lower rate of adverse events. Patients will be followed for 5 years after completion of ADT to evaluate outcomes. The primary objective will be to determine if enhanced ADT has superior 5-year failure-free survival compared to standard ADT. Secondary objectives include evaluation of chronic toxicities, quality of life impact, biochemical progression-free survival, cancer-specific survival, overall survival, and metastasis-free survival.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • PSMA-PET
  • Prostate Cancer
  • Androgen Deprivation Therapy
  • Abiraterone
  • Radiation Therapy
  • Pelvic Lymphadenopathy
  • Hormone Therapy
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histopathologically proven diagnosis of local prostate cancer. will be confirmed by UNMC pathology review if collected outside our institution.
  2. Targetable PSMA-avid pelvic lymph node measuring \<1cm in short axis diameter.
  3. No prior definitive treatment or intervention received.
  4. (ECOG) performance status ≤ 2 within 14 days prior to registration.
  5. Age ≥ 30 years.
  6. Patient must be able to provide study-specific prior to study entry.
  7. Patient must be able to swallow medications.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of distant disease outside the pelvic lymph nodes (including osseous pelvic disease).
  2. Presence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule, including alcohol dependence or drug abuse.
  3. Relative or absolute to radiation therapy as determined by the treating physician. These include, but are not limited to, inflammatory bowel disease, connective tissue disorders (systemic lupus erythematosus, scleroderma, etc.), and genetic disorders that risk increased sensitivity to radiation therapy.
  4. Severe, active co-morbidity, defined as follows:

    1. Unstable angina and/or congestive heart failure requiring hospitalization within the last 3 months prior to registration.
    2. Congestive heart failure ( functional capacity class II or greater).
    3. Transmural myocardial infarction within the last 3 months prior to registration.
    4. History of stroke or within 3 months prior to registration.
    5. Currently uncontrolled diabetes mellitus.
    6. Ongoing arrhythmias of Grade >2 [National Cancer Institute's Common Toxicity Criteria for Adverse Events (), version 5.03]; chronic stable atrial fibrillation on stable anticoagulant therapy is allowed.
    7. Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism) in the past month.
    8. Significant vascular disease (e.g., aortic aneurysm, history of aortic dissection) or peripheral vascular disease.
    9. Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.
    10. exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration.
    11. Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects.
    12. Acquired Immune Deficiency Syndrome (AIDS) based upon the current Centers for Disease Control and Prevention definition that is being treated with contraindicated medications, including but not limited to Atazanavir, Saquinavir, Ritonavir, Indinavir, or Nelfinavir. Note, however, that testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly .
    13. Uncontrolled seizures or seizures in the past 3 months. Patients can enroll if their seizures have been well-controlled for >3 months on antiseizure medications.
    14. Gastrointestinal bleeding or any other hemorrhage/bleeding event CTCAE version 5 grade 3 or greater within 30 days prior to registration.
    15. History of a non-healing wound, ulcer, or bone fracture within 90 days (3 months) prior to registration.
    16. Total ≥1.5X (ULN) [except for subjects with Gilbert's disease, in which case total bilirubin not to exceed 10X ULN], alanine () and aspartate (AST) aminotransferase >= 2.5X ULN.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Active comparator
    Standard ADT

    Participants receive standard androgen deprivation therapy (ADT) in combination with radiation therapy.

    Drug: Androgen Deprivation Therapy (ADT) · Radiation: Radiation Therapy

  • Experimental
    Abiraterone/Prednisone + Standard ADT

    Participants receive Abiraterone/Prednisone in addition to standard androgen deprivation therapy (ADT) in combination with radiation therapy

    Drug: Androgen Deprivation Therapy (ADT) · Drug: Abiraterone · Drug: Prednisone · Radiation: Radiation Therapy

Interventions

  • DrugAndrogen Deprivation Therapy (ADT)

    Standard hormone therapy used for prostate cancer treatment

    Also known as: ADT

  • Abiraterone administered as part of enhanced androgen deprivation therapy

  • Prednisone administered in combination with abiraterone

  • RadiationRadiation Therapy

    Radiation therapy administered per protocol to the prostate and/or pelvic lymph nodes

06

What researchers measure

Primary outcomes

  1. 5-year failure-free survival rate

    Determine the impact of enhanced ADT with abiraterone/prednisone versus standard ADT on the 5-year failure-free survival of patients with PSMA-positive conventionally negative pelvic lymphadenopathy (i.e. \<1cm in smallest diameter).

    Time frame: From randomization up to 5 years

Secondary outcomes

  1. Toxicity in both arms from 3 months to 2 years post-ADT.

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: From 3 months to 2 years post-ADT

  2. Evaluate and compare patient-reported symptom outcomes in both arms from 3 months to 2 years post-ADT. (IPSS)

    Using IPSS (International Prostate Symptom Score). The quality-of-life measures will be summarized using descriptive statistics at each time point collected as n, mean, SD, median, minimum, and maximum. The IPSS score ranges from 0 to 35, with higher scores indicating worse urinary symptoms.

    Time frame: From 3 months to 2 Years post-ADT

  3. Evaluate and compare patient-reported symptom outcomes in both arms from 3 months to 2 years post-ADT. (FACT-P)

    Using FACT-P (Functional Assessment of Cancer Therapy-Prostate.) The quality of life measures will be summarized using descriptive statistics at each time point collected as n, mean, SD, median, minimum, and maximum. The FACT-P score ranges from0 to 156, with higher scores indicating better quality of life.

    Time frame: From 3 months to 2 Years post-ADT

  4. Evaluate local progression-free survival (i.e., failure-free survival excluding biochemical failure).

    Evaluate progression-free survival (i.e., failure-free survival excluding biochemical failure). Progression-free survival will be estimated with the Kaplan-Meier method and will be compared between treatment arms with the log-rank test. The 5-year survival rates will be estimated with a 95% confidence interval. Time to local failure is defined as time since randomization to disease progression within the intact prostate. Regional, metastases, and deaths are treated as competing events.

    Time frame: From randomization up to 5 years

  5. Evaluate locoregional progression-free survival (i.e., failure-free survival excluding biochemical failure).

    Evaluate progression-free survival (i.e., failure-free survival excluding biochemical failure). Progression-free survival will be estimated with the Kaplan-Meier method and will be compared between treatment arms with the log-rank test. The 5-year survival rates will be estimated with a 95% confidence interval. Time to locoregional failure is defined as time since randomization to disease progression within the pelvis and pelvic lymph nodes. Metastases and deaths are treated as competing events.

    Time frame: From randomization up to 5 years

  6. Evaluate 5-year overall survival

    Overall survival will be estimated with the Kaplan-Meier method and will be compared between treatment arms with the log-rank test. The 5-year survival rates will be estimated with a 95% confidence interval. Overall survival is defined as the time since the date of randomization to the date of death or last follow-up.

    Time frame: From randomization up to 5 years

  7. Evaluate 5-year cancer-specific survival

    Cumulative incidence methods will be used to estimate 5-year rates (with 95% CI) of LC, LRC, and DM while accounting for death as a competing event. Cancer-specific survival is defined as time since the date of randomization to the date of death due to cancer diagnosis or treatment or last follow-up. Deaths due to other causes are treated as competing events.

    Time frame: From randomization up to 5 years

  8. Evaluate 5-year metastasis-free survival.

    Time to distant metastasis is defined as time since date of randomization to distant metastases in para-aortic lymph nodes and distant organs or last follow-up. Locoregional failures and deaths are treated as competing events.

    Time frame: From randomization up to 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — No Plan to Share

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Apr 2033, 79 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 79 months is above that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Sep 2026, on Oct 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 19, 2025
StartActual
Sep 1, 2026was Oct 2026
Primary completionEst.
Apr 3, 2033
CompletionEst.
Apr 3, 2033
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 15, 2026→Sep 1, 2026 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Start date Oct 15, 2026→Sep 1, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07237269
Responsible party
Sponsor
First posted
Nov 19, 2025
Start date
Sep 1, 2026
Primary completion
Apr 3, 2033 (estimated)
Completion
Apr 3, 2033 (estimated)
Last update
Oct 19, 2026

Study contacts

Taylor Johnson, MA
Contact
taylora.johnson@unmc.edu
402-559-4596
IIT OFFICE
Contact
iitoffice@unmc.edu
402-559-4596
Michael Baine, MD, PhD
principal investigator · Fred & Pamela Buffett Cancer Center, University of Nebraska, 987521 Nebraska Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abiraterone · Prednisone

Start the discussion